Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Chinese patients with active psoriatic arthritis
NCT04711902Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in psoriatic arthritis (PsA), sponsored by Novartis. Started Jun 2021; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04711902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711902.